Understanding GLP-1 medications and their impact on UK consumer behaviour

GLP-1 is a naturally occurring hormone that helps regulate appetite and blood sugar levels. Medicine that mimic or activate it (such as Ozempic or Mounjaro) have moved from just a medical story to a mainstream retail issue. The question at the beginning of 2026 is no longer whether these drugs will affect what we buy, but how quickly retailers and brands can adapt their products, products and offering as smaller-appetite, higher-quality consumption becomes normalised. In this article we consider:

Shifting consumer baskets: Approximately 5% of UK adults now use GLP-1 medications, driving measurable declines in calorie-dense snacks and increased demand for high-protein, high-fibre and nutrient-dense products.
Retailer response: Major UK grocers, including Sainsbury’s, Tesco, Marks & Spencer, Co-op and Morrisons, have launched dedicated GLP-1-aligned product ranges in early 2026.
M&A activity intensifying: Strategic acquisitions in dairy, functional beverages and chilled prepared meals are expected to continue as brands seek to capitalise on the wellness-driven consumption shift.
Pricing and format evolution: Smaller portions and mini-meals are emerging as premium propositions, with nutrient density rather than pack size becoming the rationale for higher price points.

UK grocery retailers respond to GLP-1 consumer trends: Sainsbury’s, Tesco and Greggs

Retail bosses and analysts are now explicitly linking appetite-suppressing medicines with clear shifts in retail behaviour. In mid-January, multiple UK grocers and trade press reiterated the same themes. Namely, the impact of these medicines is no longer negligible (noting that a recent report states 5% of UK adult are now using these medicines), which is now impacting sales at nationwide grocers. Secondly, shopping baskets are now leaning towards fresh, higher-protein and higher-fibre products, with a focus on smaller portions and scrutiny of nutritional claims. Finally, it has not taken retailers long to begin to curate for this shift.

Sainsbury’s has observed a switch “into healthier choices, into fresh food and fibre”. Tesco has also highlighted the performance of fresh food and higher-protein options “that work well in the GLP-1 context”. Greggs has been candid that customers are seeking smaller portions and clearer information. UK grocers have been launching GLP-1-aligned ranges in January including Marks & Spencer launching a “Nutrient Dense” range, Co-op adding “Good Fuel” mini meals and Morrisons launching a range alongside Applied Nutrition with high-protein meals which have been signposted purposefully as “GLP-1 friendly”.

GLP-1 users and grocery spending patterns: Research on consumer purchasing behaviour

Early research on spending patterns suggests households with someone using the medicine reduces overall grocery spend modestly in the first six months, with the steepest declines in calorie-dense snacks and baked goods, with relative increases in fresh produce, yoghurt and functional beverages. This suggests willingness to pay for added benefits, especially where protein, fibre and hydration are credible. For retailers, this is an invitation to adjust their offering and pricing. Smaller packs and mini-meals may no longer result in lower pricing where the health proposition is strong and nutrient density emerges as rationale for premium pricing.

Strategic recommendations for UK food brands and retailers in the GLP-1 era

Retailers and brands should now assume smaller appetites and higher expectations on nutrition are here to stay. Brands should now ensure making high-protein, high-fibre choices easy to find, treat portion control as a habit not a compromise and change packaging to give shoppers trust. Expect more credible options for single-serve meals or mini-meal options to cut waste and fit with new eating patterns. Brands will also need to react with pricing that reflects nutrition rather than simply pack size, but ensure messaging is made clear around this.

Food and beverage M&A trends 2025-2026: Protein, dairy and functional brands driving deal activity

Looking back at 2025, it is clear there was an uptick in M&A activity following usage of appetite-supressing medicines into the protein and fibre areas. Bolt-ons are the preferred route while larger portfolio moves are still being considered. In the UK dairy sector, Yeo Valley acquired gourmet yoghurt brand The Collective, bringing an already-partnered, high-protein player in-house to improve supply and scale. Müller moved on gut health leader Biotiful Dairy in a reported £100m plus deal, following its earlier purchase of milk processor Yew Tree Dairy.

Beyond dairy, Premier Foods bought Merchant Gourmet to deepen in “healthy convenience”. On the prepared foods side, Greencore’s proposed £1.2bn merger with Bakkavor points to scale in chilled meals, a category likely to benefit from smaller portion demand. Globally, the wellness theme was even more pronounced, with PepsiCo buying prebiotic soda brand Poppi and Celsius acquiring Alani Nutrition, both signalling continued appetite for functional, brands.

We expect to see a continuation in 2026, with yoghurt, yoghurt drinks and high-protein snacking, functional beverages and chilled prepared meals continuing to draw interest in the market.

GLP-1 market data: UK consumer statistics and shopping behaviour insights

A shift is emerging in both the food products purchased and the shopping habits of UK consumers. Approximately 4.1% of UK households currently use GLP-1 medications, according to AHDB.

The collateral impact includes a decline in takeaways, heavier meals, snacks, higher-fat dairy and some meat, as consumers increasingly favour GLP-1-friendly food and meal ranges. Conversely, growth is evident in fat-free and Greek yoghurt, cottage cheese, high-nutrient products, and convenient formats – including frozen, tinned and long-life options – as shoppers shift towards “little and often” purchasing patterns.

GLP-1 users are also less likely to shop at large supermarkets, with 44% of UK users reporting a new go-to retailer as they seek out those offering healthier items.

Industry bodies and commentators suggest UK food businesses should:

Prioritise high-protein, high-fibre and nutrient-dense product development
Lean into convenience formats such as frozen and tinned categories
Explore the convenience store channel given GLP-1 users’ shopping preferences
Introduce family-friendly options, since most UK GLP-1 users live with partners and children
Focus on affluent consumers for now whilst preparing for wider NHS rollout of GLP-1

As AHDB analyst Vanessa Adamson noted: “As more consumers are expected to try GLP-1 weight-loss drugs in 2026, lean primary red meat, natural yogurt, milk and eggs are likely to be popular, as these consumers are actively seeking nutrient-dense meals in smaller portions that are packed with protein for muscle maintenance.”

Conclusion: The future of UK retail and M&A in a GLP-1 driven market

GLP-1 based medicines are accelerating a pre-existing shift towards healthier, higher-protein and higher-fibre consumption, portion control and clearer nutritional information. UK retailers have begun to explicitly account for this change and recent product launches emphasise this. This change may set the tone for the year ahead. The implication for brands and buyers is to move now. Those who re-size and reformulate portfolios, lean into partnerships, pursue bolt-ons may outpace the market. The businesses that re-align fastest with a focus around smaller-appetite, higher-quality consumption will be best placed as this grows from just a fad to a health-seeking typical behaviour shift. In short, smaller appetites are driving bigger shifts, on the shelf and at the deal table.